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Conclusion: The combination of nonspecific clinical signs
(pain, dyspepsia) with biochemical markers of biliary pathology
and endocrine pancreatic insufficiency – of PCa patients demon-
strates the obligatoriness of differential diagnostic pancreatic and
biliary pathology in their earlier stages.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.027
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Acute myelomonocytic leukemia (FAB M4) is one of the most
common forms of acute myeloid leukemia (AML). This AML form
is characterized by rapid accumulation transformed myeloblasts
and monoblasts in bone marrow, with the rapid suppression of
normal hematopoiesis. Bone marrow microenvironment is one
of the main factors determining drug resistance of leukemic cells.
It is known that the adhesion of leukemic cells to mesenchymal
stem cell and bone marrow extracellular matrix (laminin,
collagen) enhances their drug resistance. However, it remains
unknown whether the emergence of drug resistance when
cell–cell contacts are formed only between leukemia cells,
without the involvement of bone marrow stromal elements. We
studied the role of cell aggregation in drug resistance of leukemic
cells. We used the bone marrow mononuclear cells (BMMC)
isolated from the patients with acute myelomonocytic leukemia.
For the formation of multicellular aggregates, BMMC were
cultivated in 96-well plates coated with 1.5% agarose. We showed
that resistance of BMMC to bortezomib, doxorubicin and
fludarabine in multicellular aggregates was increased. In three-
dimensional multicellular aggregates of BMMC index IC50 for
bortezomib, doxorubicin and fludarabine was 7 ± 1 ng/ml,
1 ± 0.4 mkM and 0.8 ± 0.05 mkM, respectively. In control condi-
tion, index IC50 bortezomib, doxorubicin and fludarabine was
significantly lower, 2 ± 0.5 ng/ml, 0.3 ± 0.05 mkM and 0.07 ±
0.001 mkM, respectively. In multicellular aggregates of BMMC
number of mitotic cells and expression of Ki-67 protein were
not significantly different from the control. It has also been
shown that cells in multicellular aggregates increased expression
antiapoptotic protein Bcl-2. Suppression of BMMC aggregation by
culturing the cells in medium containing 0.9% methylcellulose
resulted in decreased IC50 index for bortezomib, doxorubicin
and fludarabine, 2 ± 0.7 ng/ml, 0.12 ± 0.004 mkM and 0.04
± 0.005 mkM, respectively. Expression of the Bcl-2 protein was
also decreased. This work demonstrates the involvement of cell
aggregation in the formation of drug resistance phenotype in
leukemic cells.
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Blood-derived biomarkers, such as circulating tumour cells
(CTCs) and circulating tumour DNA (ctDNA), are a valuable source
of molecular genetic data for tumours they spring from. In trans-
lational cancer research, the ‘‘liquid biopsy” concept has been put
forward to denote the detection and molecular characterization
of these biomarkers.
The idea of liquid biopsy is based on a hypothesis that profiles
of somatic mutations in CTCs and ctDNA are identical to those in
the original tumour. Therefore, the mutation status of the source
tumour can be revealed through the molecular analysis of the
CTCs and ctDNA obtained from the blood. The major advantages
of liquid biopsy are an essentially decreased invasiveness (no
need for tissue biopsy, surgery or bronchoscopy) and an ability
to carry out the analysis at patient’s follow up (e.g. to monitor
for residual disease).
However, both the CTCs and ctDNA are not abundant in the
bloodstream and their capture is technically challenging. Also,
due to tumour heterogeneity, the CTCs may not fully represent
the entire tumour, while ctDNA is naturally fragmented and
degraded, so its utility for genetic analysis may be limited. Finally,
the DNA extracted from CTCs and, especially, ctDNA are ‘‘con-
taminated” by DNA from non-tumour cells from the bloodstream
raising a challenge of detecting mutant DNA among significantly
prevailing wild-type DNA.
Some of these issues can be overcome by using such advanced
techniques as BEAMing, digital PCR or ultra-deep sequencing, but
their use in standard clinical settings is limited by the need for
special equipment and associated costs. Inexpensive and less
sophisticated, but still highly sensitive and specific, approaches,
such as COLD-PCR or wild-type blocking PCR, are also available
to detect ‘‘druggable” mutations in CTCs and ctDNA.
Application of these approaches of liquid biopsy in clinical
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